Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen

Corbin J. Eule,Adam Warren,Elizabeth Molina Kuna,Eryn B. Callihan,Simon P. Kim,Thomas W. Flaig

DOI: https://doi.org/10.1016/j.urology.2024.04.034

IF: 1.555

2024-04-29

Urology journal

Abstract:Objective To determine whether neoadjuvant gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete response (pCR) for patients with muscle-invasive bladder cancer (MIBC) with secondary analyses of pathological downstaging and toxicity. Materials and Methods This systematic review and meta-analysis identified studies of patients with MIBC treated with neoadjuvant GC compared to ddMVAC from PubMed, Web of Science, and EMBASE. Random-effect models for pooled log-transformed hazard ratios (HR) for OS and PFS and pooled odds ratios (OR) for pCR and downstaging were developed using the generic inverse variance method and Mantel-Haenszel method, respectively. Results Ten studies were identified (4 OS, 2 PFS, and 6 pCR clinical endpoints). Neoadjuvant ddMVAC improved OS (HR 0.71 [95% CI 0.56; 0.90]), PFS (HR 0.76 [95% CI 0.60; 0.97]), and pathological downstaging (OR 1.34 [95% confidence interval 1.01; 1.78]) as compared to GC. There was no significant difference between regimens for pCR rates (odds ratio 1.38 [95% confidence interval 0.90; 2.12]). Treatment toxicity was greater with ddMVAC. Limitations result from differences in number of ddMVAC cycles and patient selection between studies. Conclusions Neoadjuvant ddMVAC is associated with improved overall survival and progression-free survival versus gemcitabine/cisplatin for patients with muscle-invasive bladder cancer prior to radical cystectomy. Although rates of pathological complete response were not significantly different, pathological downstaging correlated with overall survival. Dose-dense MVAC should be preferred over gemcitabine/cisplatin for patients with muscle-invasive bladder cancer who can tolerate its greater toxicity.

urology & nephrology